U.S. flag

An official website of the United States government

NM_001367916.1(MAGT1):c.462T>A (p.Tyr154Ter) AND X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Nov 3, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003641422.1

Allele description

NM_001367916.1(MAGT1):c.462T>A (p.Tyr154Ter)

Gene:
MAGT1:magnesium transporter 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq21.1
Genomic location:
Preferred name:
NM_001367916.1(MAGT1):c.462T>A (p.Tyr154Ter)
HGVS:
  • NC_000023.11:g.77857426A>T
  • NG_016390.1:g.43143T>A
  • NM_001367916.1:c.462T>AMANE SELECT
  • NM_032121.5:c.558T>A
  • NP_001354845.1:p.Tyr154Ter
  • NP_115497.4:p.Tyr186Ter
  • LRG_353t1:c.558T>A
  • LRG_353:g.43143T>A
  • LRG_353p1:p.Tyr186Ter
  • NC_000023.10:g.77112923A>T
Protein change:
Y154*
Molecular consequence:
  • NM_001367916.1:c.462T>A - nonsense - [Sequence Ontology: SO:0001587]
  • NM_032121.5:c.558T>A - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia
Identifiers:
MONDO: MONDO:0010455; MedGen: C3275445; Orphanet: 317476; OMIM: 300853

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004403770Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Nov 3, 2022)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.

Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ.

Blood. 2014 Apr 3;123(14):2148-52. doi: 10.1182/blood-2013-11-538686. Epub 2014 Feb 18. Review.

PubMed [citation]
PMID:
24550228
PMCID:
PMC3975255

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV004403770.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with MAGT1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Tyr186*) in the MAGT1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MAGT1 are known to be pathogenic (PMID: 24550228).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 28, 2024